Skip to main content

$0.080 0.005 (6.67%)

High

$0.08

Low

$0.08

Trades

10

Turnover

$19,245

Volume

244,049
30 June 2023 at 1:52pm
Register to track NSB and receive email alerts.
Subject
NSB Ann: Change of Director's Interest Notice - Rennie

NSB Ann: Change of Director's Interest Notice - Uvarov

NSB Ann: Change of Director's Interest Notice - Rennie

NSB Ann: Change of Director's Interest Notice - Uvarov

NSB Ann: Change of Director's Interest Notice - Rennie

NSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NSB Ann: Positive treatment effect in MS animal study

NSB Ann: Half Yearly Report and Accounts

NSB Ann: Notification of cessation of securities - NSB

NSB Ann: Investor Update Presentation

NSB Ann: Investor Update Webinar

NSB Ann: R&D Tax Incentive Refund Received

NSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NSB Ann: Patent Application - Updated Announcement

NSB Ann: NSB files new patent

NSB Ann: Results of Meeting

NSB Ann: Chair's address to shareholders & AGM presentation

NSB Ann: Appointment of Interim CEO

NSB Ann: Executive Management Changes

NSB Ann: NSB receives R&D Advance & Overseas Finding

NSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NSB Ann: Notice of Annual General Meeting

NSB Ann: Investor Update Presentation

NSB Ann: Investor Update Webinar

NSB Ann: Final Director's Interest Notice - Liddelow

NSB Ann: CEO Resignation

NSB Ann: Investor Update Webinar

NSB Ann: HREC decision to not approve Phase I Clinical Trial

NSB Ann: Corporate Governance Statement

NSB Ann: Appendix 4G

NSB Ann: NeuroScientific releases FY2022 Results

NSB Ann: 2022 Annual Report and Appendix 4E

NSB Ann: R&D Tax Incentive Refund Received

NSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NSB Ann: HREC Submission for Phase I Clinical Trial

NSB Ann: First Subject Recruited for Early-Phase Clinical Trial

NSB Ann: Notification of cessation of securities - NSB

NSB Ann: Company Presentation - Gold Coast Investment Showcase

NSB Ann: Clarification of Results in MS Animal Study

NSB Ann: Notification regarding unquoted securities - NSB

NSB Ann: Issue of Employee Options

NSB Ann: Positive results in MS animal study

NSB Ann: Ethics Approval Granted for Early-Phase Clinical Trial

NSB Ann: HREC Submission for early-phase Clinical Trial

NSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NSB Ann: Positive safety result supports advance to clinical trials

NSB Ann: NSB Enhances Management Team

NSB Ann: Company Presentation

NSB Ann: NSB presenting at Broker Briefing Investor Webinar

NSB Ann: New data demonstrates EmtinB activity in autoimmune diseases

Register to track NSB and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX